Genesys BioLabs introduces PAULA's test for early lung cancer detection

Genesys BioLabs, a division of 20/20 GeneSystems, Inc. announces today the launch of PAULA's test, a blood test for the early detection of lung cancer, addressing the need for a widely useable early detection protocol for asymptomatic patients. The test was introduced to several dozen D.C. area physicians over the past several weeks including a group of lung cancer specialists who attended this past weekend's Lung Cancer 2012 conference at the Hotel Monoco in Washington, D.C.

"The reception we are receiving from doctors to our announcement of the availability of this test has been outstanding," says John Gillespie, MD, Genesys BioLabs' Medical Director. "Physicians know that patients have an 80% five year survival rate if lung cancer is caught early (stage 1A). We're fortunate to now have a test that physicians can use to test for lung cancer."

Currently, lung cancer is most often detected in the late stages when patients develop symptoms and is associated with poor prognosis. "This blood test will allow physicians to greatly improve detection of early-stage lung cancer in asymptomatic patients where treatment will dramatically improve survival," said Dr. Gillespie. He further added, "early detection saves lives."

Genesys BioLabs' test was developed over a period of five years and has been tested using over 1,500 different patient samples. The test has been analytically validated under rigorous scientific and regulatory controls and will be performed in a CLIA-approved laboratory. The test detects a panel of protein biomarkers in the blood that are associated with early lung cancer and will be initially offered to area primary care physicians to help them identify patients at the highest risk of having lung cancer. A larger national roll out is anticipated in about 18-24 months.